Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LENZ Therapeutics

Pre-Mkt 12-16 08:18:23 EST

17.08

-1.06

-5.84%

盘前17.32

+0.24+1.43%

08:18 EST

High19.62	Low16.63	Vol2.35M
Open19.38	D1 Closing18.14	Amplitude16.48%
Mkt Cap534.43M	Tradable Cap268.03M	Total Shares31.29M
T/O41.46M	T/O Rate14.98%	Tradable Shares15.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":17.08,"timestamp":1765832400000,"preClose":18.14,"halted":0,"volume":2350081,"hourTrading":{"tag":"盘前","latestPrice":17.3236,"preClose":17.08,"latestTime":"08:18 EST","volume":921,"amount":15872.295723,"timestamp":1765891093268},"delay":0,"floatShares":15692500,"shares":31289969,"eps":-1.898372,"marketStatus":"Pre-Mkt","change":-1.06,"latestTime":"12-16 08:18:23 EST","open":19.375,"high":19.62,"low":16.63,"amount":41464328.596746996,"amplitude":0.164829,"askPrice":17.37,"askSize":39,"bidPrice":16.68,"bidSize":39,"shortable":3,"etf":0,"ttmEps":-1.898372,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765895400000},"marketStatusCode":1,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":17.08,"preHourTrading":{"tag":"盘前","latestPrice":17.3236,"preClose":17.08,"latestTime":"08:18 EST","volume":921,"amount":15872.295723,"timestamp":1765891093268},"postHourTrading":{"tag":"盘后","latestPrice":17.9,"preClose":17.08,"latestTime":"19:59 EST","volume":27419,"amount":479620.6485,"timestamp":1765846764552},"volumeRatio":1.170639480959132,"impliedVol":1.0186,"impliedVolPercentile":0.8324},"requestUrl":"/m/hq/s/LENZ/tweets","defaultTab":"tweets","newsList":[{"id":"2591967429","title":"Cynata Therapeutics' Recruitment Completion for Acute Graft Versus Host Disease Clinical Trial Provides Reference for Results Timing, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2591967429","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591967429?lang=en_us&edition=fundamental","pubTime":"2025-12-16 11:12","pubTimestamp":1765854732,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics' (ASX:CYP) completion of recruitment for its acute graft versus host disease clinical trial provides a clear line of sight to the timing of top-line results from the company's clin","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4218","HST","BK4585","BK7067","BK7508","BK4539","BK4007","LENZ","BK4588","BK7501","CYP.AU","BK4181","BK4139"],"gpt_icon":0},{"id":"2591627044","title":"Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis","url":"https://stock-news.laohu8.com/highlight/detail?id=2591627044","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591627044?lang=en_us&edition=fundamental","pubTime":"2025-12-16 06:39","pubTimestamp":1765838340,"startTime":"0","endTime":"0","summary":"Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel)Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with Options for Japan and C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/15/3205901/0/en/Allogene-Therapeutics-Reports-Favorable-Result-for-Servier-in-Arbitration-with-Cellectis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","CLLS","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2591665647","title":"Silexion Therapeutics Initiated at Buy by Litchfield Hills","url":"https://stock-news.laohu8.com/highlight/detail?id=2591665647","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591665647?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:55","pubTimestamp":1765810500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SLXN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 15, 2025 09:55 ET (14:55 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4539","BK4007","BK4139","LENZ"],"gpt_icon":0},{"id":"2591473566","title":"Silence Therapeutics Says CEO Craig Tooman Leaving","url":"https://stock-news.laohu8.com/highlight/detail?id=2591473566","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591473566?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:49","pubTimestamp":1765810148,"startTime":"0","endTime":"0","summary":"Silence Therapeutics  said Monday that Chief Executive and President Craig Tooman \"agreed by mutual consent\" to terminate his employment with the company, effective Dec. 14.Board Chair Iain Ross will lead Silence on an interim basis, effective immediately, the company said.Silence shares were down 2% in early trading Monday.Price: 6.20, Change: -0.13, Percent Change: -1.98","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4139","BK4007","LENZ","SLN"],"gpt_icon":0},{"id":"2591644495","title":"Stoke Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2591644495","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591644495?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:09","pubTimestamp":1765807740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/STOK/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 15, 2025 09:09 ET (14:09 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2591649977","title":"Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649977","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591649977?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:00","pubTimestamp":1765803600,"startTime":"0","endTime":"0","summary":"SHANGHAI and SANTA BARBARA, Calif., Dec. 15, 2025 /PRNewswire/ -- Rona Therapeutics, a clinical-stage RNAi company, today announced the recent completion of Cohort 1 dosing in its Phase 1 first-in-human clinical study of RN3161, an investigational GalNAc-conjugated siRNA targeting INHBE for obesity treatment. Cohort 1 was completed successfully with a favorable initial safety and tolerability profile, marking the first clinical milestone for Rona's INHBE program.Scientific and industry interest in INHBE has accelerated, supported by compelling human genetic evidence and emerging clinical observations. RN3161 is designed for deep and durable silencing of INHBE with once- or twice-yearly dosing, enabling a differentiated therapeutic profile for obesity treatment.\"We are pleased to report successful completion of our first cohort in this Phase 1 trial, an important step in advancing RN3161 and validating the potential of INHBE as a new metabolic target,\" said Alex M. DePaoli, MD, CMO. \"Th","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2845387/Rona_Therapeutics_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2845387/Rona_Therapeutics_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/rona-therapeutics-advances-inhbe-sirna-into-phase-1-clinical-development-302642058.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","BK4139","LENZ"],"gpt_icon":0},{"id":"2591125666","title":"Enliven Therapeutics (ELVN): Taking Stock of Valuation After Leadership Shift and Upcoming ELVN-001 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591125666","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591125666?lang=en_us&edition=fundamental","pubTime":"2025-12-15 14:18","pubTimestamp":1765779487,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics (ELVN) just reshuffled its top ranks, naming industry veteran Richard Fair as CEO, President, and board member, while co founder Sam Kintz shifts to Head of Pipeline to focus on R and D.\nSee our latest analysis for Enliven Therapeutics.\nThe leadership shake up lands after a rough stretch for the stock, with a 7 day share price return of minus 22.7 percent and a 1 year total shareholder return of minus 27.17 percent. This suggests momentum has been fading despite the late...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/enliven-therapeutics-elvn-taking-stock-of-valuation-after-le","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/enliven-therapeutics-elvn-taking-stock-of-valuation-after-le","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","BK4139","ELVN","BK4539","LENZ"],"gpt_icon":0},{"id":"2591691830","title":"Prescient Therapeutics Secures European Authorization to Start Clinical Trial in Italy; Shares Hit Two-Year High","url":"https://stock-news.laohu8.com/highlight/detail?id=2591691830","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591691830?lang=en_us&edition=fundamental","pubTime":"2025-12-15 11:06","pubTimestamp":1765767988,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics (ASX:PTX) secured authorization from the European Clinical Trials Information System to begin its clinical trial for cancer drug candidate PTX-100 in patients with relapsed/refr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","PTX.AU","BK4539","BK4139","LENZ","BK4007","BK7067"],"gpt_icon":0},{"id":"2591431655","title":"Press Release: Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout","url":"https://stock-news.laohu8.com/highlight/detail?id=2591431655","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591431655?lang=en_us&edition=fundamental","pubTime":"2025-12-14 04:53","pubTimestamp":1765659180,"startTime":"0","endTime":"0","summary":"-- Expands Sobi's pipeline with a highly differentiated new Phase 3 asset in. \"The acquisition of Arthrosi allows us to expand our gout pipeline with a highly differentiated new asset\", said Guido Oelkers, President and CEO of Sobi. \"Pozdeutinurad has the potential to become the therapy of choice for patients who have progressive gout with persistent and unresolved symptoms despite first-line therapy. The product has the potential to materially accelerate our growth until the mid 2030s, and beyond. We welcome all members of the talented Arthrosi team and are looking forward to working closely together to be able to offer this therapy to patients as soon as possible.\". \"We are thrilled to join forces with Sobi and look forward to working together to ensure a seamless transition as they advance pozdeutinurad towards pivotal data and potential regulatory filings. We believe that Sobi's global expertise in commercialisation will accelerate our shared mission to deliver pozdeutinurad's pote","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","R","BK4022","BK4007","BK4539","LENZ","BK4232"],"gpt_icon":0},{"id":"2591816006","title":"Lenz Therapeutics- Aware of Recent Adverse Event Report Submitted to the FDA - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2591816006","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591816006?lang=en_us&edition=fundamental","pubTime":"2025-12-13 05:26","pubTimestamp":1765574804,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XI0QJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LENZ","BK4139","BK4539"],"gpt_icon":0},{"id":"2591568198","title":"Lenz Therapeutics - Adverse Event Reporting System Database Describing a Retinal Tear in a Patient Using Vizz (Aceclidine Ophthalmic Solution) 1.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591568198","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591568198?lang=en_us&edition=fundamental","pubTime":"2025-12-13 05:26","pubTimestamp":1765574804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XI0QJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LENZ","BK4139","BK4539","BK4007"],"gpt_icon":0},{"id":"2591683493","title":"Structure Therapeutics Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2591683493","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591683493?lang=en_us&edition=fundamental","pubTime":"2025-12-13 01:23","pubTimestamp":1765560180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GPCR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2025 12:23 ET (17:23 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2591203500","title":"Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup","url":"https://stock-news.laohu8.com/highlight/detail?id=2591203500","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591203500?lang=en_us&edition=fundamental","pubTime":"2025-12-13 00:00","pubTimestamp":1765555200,"startTime":"0","endTime":"0","summary":"– Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impact","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/12/3204783/0/en/Mineralys-Therapeutics-Phase-3-Launch-HTN-Trial-of-Lorundrostat-Recognized-in-Inaugural-Journal-of-the-American-Medical-Association-JAMA-Research-of-the-Year-Roundup.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1162221912.USD","BK4585","BK4007","BK4097","BK4139","LENZ","BK4539","BK4107","BK4117","LU0162691827.USD","LU0320765646.SGD","BK4588","BK4167","AFG","LU1829250122.USD","AHI","BP","LU0072461881.USD","BK4201"],"gpt_icon":0},{"id":"2590850914","title":"Structure Therapeutics Is Maintained at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2590850914","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590850914?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:05","pubTimestamp":1765544700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GPCR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2025 08:05 ET (13:05 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2590505613","title":"RBC Cuts Price Target on Applied Therapeutics to $0.25 From $1, Keeps Sector Perform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2590505613","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590505613?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:01","pubTimestamp":1765540893,"startTime":"0","endTime":"0","summary":"RBC Cuts Price Target on Applied Therapeutics to $0.25 From $1, Keeps Sector Perform, Speculative Risk","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ"],"gpt_icon":0},{"id":"2590508231","title":"Autolus Therapeutics Price Target Maintained With a $10.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2590508231","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590508231?lang=en_us&edition=fundamental","pubTime":"2025-12-12 19:12","pubTimestamp":1765537920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AUTL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2025 06:12 ET (11:12 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Autolus Therapeutics Price Target Maintained With a $10.00/Share by Needham","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2590192524","title":"Argenica Therapeutics' AI-Driven Reanalysis of Phase 2 Stroke Trial Shows Commercially Meaningful Benefit, Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2590192524","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590192524?lang=en_us&edition=fundamental","pubTime":"2025-12-12 12:03","pubTimestamp":1765512212,"startTime":"0","endTime":"0","summary":"Argenica Therapeutics'  artificial intelligence-driven reanalysis of its phase 2 stroke trial provide compelling evidence of ARG-007's clinically and commercially meaningful benefit in patients with severe stroke, said Euroz Hartleys in a Thursday note.The research firm said that the phase 2 trial has effectively served its purpose: to characterize the drug's activity and identify the patients most likely to benefit.Euroz Hartleys believes that the totality of evidence is more than sufficient to justify advancing into a targeted phase 2b trial enriched for patients most likely to respond, thereby maximizing the probability of success.Euroz Hartleys maintained its speculative buy rating on AGN with a price target of AU$1.30.Argenica Therapeutics' shares fell past 3% in recent Friday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","BK7096","BK4007","BK4539","AGN.AU"],"gpt_icon":0},{"id":"2590562541","title":"Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry","url":"https://stock-news.laohu8.com/highlight/detail?id=2590562541","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590562541?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:15","pubTimestamp":1765487700,"startTime":"0","endTime":"0","summary":"HUNTSVILLE, Dec.  11, 2025  (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc.(“Serina” or the \"Company\") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3204315/0/en/Serina-Therapeutics-Strengthens-Leadership-Team-with-Appointment-of-Dr-Joshua-Thomas-as-VP-Head-of-Chemistry.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","BK4231","BK4080","LENZ","BK4139","TISI","ADC","BK4120"],"gpt_icon":0},{"id":"2590549965","title":"Press Release: Oruka Therapeutics Announces New Board Member and Board Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2590549965","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590549965?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486860,"startTime":"0","endTime":"0","summary":"MENLO PARK, Calif., Dec. 11, 2025  -- Oruka Therapeutics, Inc.  , a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis , today announced the appointment of Chris Martin to its Board of Directors. Additionally, Cameron Turtle, DPhil, resigned from the Board effective December 11, 2025.\"As we rapidly advance our co-lead programs through development, I'm pleased to announce this board transition at Oruka,\" said Lawrence Klein, PhD, Chief Executive Officer of Oruka Therapeutics. \"Chris's expertise can bring tremendous value to the company as we advance towards late-stage development and think more concretely about how ORKA-001 and -002 could enter the market. We have greatly valued Cameron's contributions on our Board in helping to shape our strategy and direction in the early stages of building our company, and I would like to personally thank him on behalf of our Board for hi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","BK4539","LENZ","ORKA"],"gpt_icon":0},{"id":"2590499345","title":"Press Release: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs","url":"https://stock-news.laohu8.com/highlight/detail?id=2590499345","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590499345?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486860,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Dec. 11, 2025  -- Structure Therapeutics Inc. , a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the closing of its previously announced upsized underwritten public offering of 9,961,538 American depositary shares , each representing three ordinary shares, which includes the full exercise of the underwriters' option to purchase up to 1,500,000 additional ADSs at a price to the public of $65.00 per ADS and pre-funded warrants to purchase 1,538,462 ADSs at a price to the public of $64.9999 per pre-funded warrant. All of the securities in the offering were sold by Structure Therapeutics.The gross proceeds to Structure Therapeutics from the offering were approximately $747.5 million, before deducting underwriting discounts and commissions and offering expenses.Jefferies, Leerink Partners, Goldman Sachs & Co. LLC, Morgan Stanley, Guggenheim Securities and BMO Ca","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0912757837.SGD","BK4516","LU0158827781.USD","LU2028103732.USD","BK4127","BK4504","LU1074936037.SGD","LU0106831901.USD","LU1244550494.USD","LU0267386448.USD","LU1720051108.HKD","BK4581","LU0106261372.USD","LU0557290698.USD","LU0320765646.SGD","LENZ","LU1732800096.USD","GPCR","LU0006306889.USD","LU1791710582.SGD","LU2089284900.SGD","LU1668664300.SGD","LU0234570918.USD","LU1720051017.SGD","LU1989772923.USD","LU2023251221.USD","LU1548497426.USD","LU0098860793.USD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4139","LU0314104364.USD","BK4539","LU0528227936.USD","LU1989772840.SGD","LU2357305700.SGD","LU0795875086.SGD","LU0795875169.SGD","LU0882574139.USD","BK4534","BK4007","LU2133065610.SGD","BK4588","LU2271345857.HKD","LU1244550221.USD","LU1244550577.SGD","LU1732799900.SGD","LU2089283258.USD","LU2111349929.HKD","LU0225283273.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.graphitebio.com","stockEarnings":[{"period":"1week","weight":-0.3605},{"period":"1month","weight":-0.3328},{"period":"3month","weight":-0.5863},{"period":"6month","weight":-0.4312},{"period":"1year","weight":-0.4485},{"period":"ytd","weight":-0.4084}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0314},{"period":"6month","weight":0.1394},{"period":"1year","weight":0.1266},{"period":"ytd","weight":0.1615}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.169631},{"month":2,"riseRate":0.5,"avgChangeRate":0.077415},{"month":3,"riseRate":0.25,"avgChangeRate":-0.098838},{"month":4,"riseRate":0.5,"avgChangeRate":-0.02248},{"month":5,"riseRate":0.25,"avgChangeRate":-0.134416},{"month":6,"riseRate":0.75,"avgChangeRate":0.05507},{"month":7,"riseRate":0.6,"avgChangeRate":0.05308},{"month":8,"riseRate":0.4,"avgChangeRate":0.016536},{"month":9,"riseRate":0.6,"avgChangeRate":0.026875},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.031334}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction